The Global Hypoglycemic Drugs Market Growth Accelerated By Emerging Demand In Developing Countries
Hypoglycemic Drugs Market |
Hypoglycemic drugs help reduce blood sugar levels for
diabetes treatment and management. Various products are available in oral and
injectable forms for type-1 and type-2 diabetes patients to regulate blood
sugar throughout the day. The demand for these drugs is rising significantly
owing to the growing prevalence of diabetes globally.
The global Hypoglycemic Drugs Market is estimated to be
valued at US$ 830.27 Mn in 2024 and is expected to exhibit a CAGR of 7.6% over the forecast period
2024 to 2031, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The demand for hypoglycemic drugs is witnessing high growth in developing
countries owing to improving access to healthcare facilities and diagnosis of
diabetes. As per the International Diabetes Foundation, around 98 million
people in India suffered from diabetes in 2019. China has the world's largest
diabetic population of around 116 million. Growing awareness initiatives by
healthcare organizations and governments are encouraging more people to get
screened and opt for timely treatment in these countries. As diabetes cases
continue to rise in emerging economies at a higher rate than developed nations,
the market for hypoglycemic drugs is expected to gain strong momentum over the
forecast period primarily driven by expanding sales volumes in Asia Pacific and
other developing regions globally.
Segment Analysis
The global hypoglycemic drugs market is dominated by oral antidiabetic
drugs sub segment, which captures around 65% of the total market share. This is
because oral drugs are preferred first line treatment for diabetes management
owing to their ease of administration and cost effectiveness as compared to
insulin drugs. Within oral antidiabetic drugs, sulfonylureas has been the
largest and dominating category historically, however DPP-4 inhibitors sub segment
is witnessing higher growth trajectory due to better safety and tolerability
profile.
Key Takeaways
The global
Hypoglycemic Drugs Market analysis is estimated to be valued at US$
830.27 Mn in 2024 and is expected to exhibit a CAGR of 7.6% over the forecast period
2024 to 2031.
Regional analysis related content
comprises
The North American region currently dominates the hypoglycemic drugs market
owing to growing incidence of diabetes, strong reimbursement structure, higher
healthcare spending and presence of key market players in the region. However,
Asia Pacific region is projected to witness highest growth during the forecast
period due to rising geriatric population, growing obesity, sedentary lifestyle
in developing countries like India and China which is propelling the diabetes
patient pool.
Key players related content comprises
Key players operating in the hypoglycemic drugs market are Pfizer Inc.,
Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC,
Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers
Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC).
Get more insights on this topic: https://www.newswirestats.com/hypoglycemic-drugs-market-industry-insights-trends-hypoglycemic-drugs-market/
Explore more information on this topic, Please visit: https://lotstoexpress.com/gummy-bliss-tasty-health-booster-for-a-vibrant-you-chewable-wellness-wonder/
Comments
Post a Comment